152 related articles for article (PubMed ID: 33768319)
21. Distinction of benign sebaceous proliferations from sebaceous carcinomas by immunohistochemistry.
Cabral ES; Auerbach A; Killian JK; Barrett TL; Cassarino DS
Am J Dermatopathol; 2006 Dec; 28(6):465-71. PubMed ID: 17122489
[TBL] [Abstract][Full Text] [Related]
22. Molecular Genetics of Sebaceous Neoplasia.
North JP
Surg Pathol Clin; 2021 Jun; 14(2):273-284. PubMed ID: 34023105
[TBL] [Abstract][Full Text] [Related]
23. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
[TBL] [Abstract][Full Text] [Related]
24. p53 staining correlates with tumor type and location in sebaceous neoplasms.
Shalin SC; Sakharpe A; Lyle S; Lev D; Calonje E; Lazar AJ
Am J Dermatopathol; 2012 Apr; 34(2):129-35; quiz 136-8. PubMed ID: 22441365
[TBL] [Abstract][Full Text] [Related]
25. Coexistence of
Rusinek D; Pfeifer A; Krajewska J; Oczko-Wojciechowska M; Handkiewicz-Junak D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Cyplinska R; Zembala-Nozynska E; Chekan M; Chmielik E; Kropinska A; Lamch R; Jurecka-Lubieniecka B; Jarzab B; Czarniecka A
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200646
[No Abstract] [Full Text] [Related]
26. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
27. TERT promoter mutations: a genetic signature of benign and malignant thyroid tumours occurring in the context of tinea capitis irradiation.
Boaventura P; Batista R; Pestana A; Reis M; Mendes A; Eloy C; Sobrinho-Simões M; Soares P
Eur J Endocrinol; 2017 Jan; 176(1):49-55. PubMed ID: 27760791
[TBL] [Abstract][Full Text] [Related]
28. TERTp mutations and p53 expression in head and neck cutaneous basal cell carcinomas with different aggressive features.
Castanheira A; Vieira MJ; Pinto M; Dias C; Prada L; Macedo S; Fernandes MS; Vieira F; Soares P; Mota A; Lopes JM; Boaventura P
Sci Rep; 2021 May; 11(1):10395. PubMed ID: 34001963
[TBL] [Abstract][Full Text] [Related]
29. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
Melo M; Gaspar da Rocha A; Batista R; Vinagre J; Martins MJ; Costa G; Ribeiro C; Carrilho F; Leite V; Lobo C; Cameselle-Teijeiro JM; Cavadas B; Pereira L; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2017 Jun; 102(6):1898-1907. PubMed ID: 28323937
[TBL] [Abstract][Full Text] [Related]
30. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia.
Singh RS; Grayson W; Redston M; Diwan AH; Warneke CL; McKee PH; Lev D; Lyle S; Calonje E; Lazar AJ
Am J Surg Pathol; 2008 Jun; 32(6):936-42. PubMed ID: 18551751
[TBL] [Abstract][Full Text] [Related]
31. Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences.
Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Caniego-Casas T; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; García Á; Ibarra J; Hakim S; Guarch R; López-Guerrero JA; Poveda A; Palacios J
Am J Surg Pathol; 2020 May; 44(5):649-656. PubMed ID: 32294063
[TBL] [Abstract][Full Text] [Related]
32. Sebaceous Tumors of the Skin: A Study of 145 Lesions From 136 Patients Correlating Pathologic Features and DNA Mismatch Repair Staining Pattern.
Konstantinova AM; Kastnerova L; Michal M; Kolm I; Kazakov DV
Am J Dermatopathol; 2021 Mar; 43(3):174-181. PubMed ID: 33201015
[TBL] [Abstract][Full Text] [Related]
33. Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age.
Liau JY; Liao SL; Hsiao CH; Lin MC; Chang HC; Kuo KT
Hum Pathol; 2014 Mar; 45(3):533-9. PubMed ID: 24440092
[TBL] [Abstract][Full Text] [Related]
34. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of universal immunohistochemical screening of sebaceous neoplasms in a service setting.
Schon K; Rytina E; Drummond J; Simmonds J; Abbs S; Sandford R; Tischkowitz M
Clin Exp Dermatol; 2018 Jun; 43(4):410-415. PubMed ID: 29333623
[TBL] [Abstract][Full Text] [Related]
36. Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
Panero J; Alves-Paiva RM; Roisman A; Santana-Lemos BA; Falcão RP; Oliveira G; Martins D; Stanganelli C; Slavutsky I; Calado RT
Am J Hematol; 2016 May; 91(5):481-5. PubMed ID: 26852175
[TBL] [Abstract][Full Text] [Related]
37. Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features.
Hissong E; Ramrattan G; Zhang P; Zhou XK; Young G; Klimstra DS; Shia J; Fernandes H; Yantiss RK
Am J Surg Pathol; 2018 Apr; 42(4):453-462. PubMed ID: 29438172
[TBL] [Abstract][Full Text] [Related]
38. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
Wang K; Liu T; Ge N; Liu L; Yuan X; Liu J; Kong F; Wang C; Ren H; Yan K; Hu S; Xu Z; Björkholm M; Fan Y; Zhao S; Liu C; Xu D
Oncotarget; 2014 Dec; 5(23):12428-39. PubMed ID: 25474136
[TBL] [Abstract][Full Text] [Related]
39. Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology.
Pfarr N; Darb-Esfahani S; Leichsenring J; Taube E; Boxberg M; Braicu I; Jesinghaus M; Penzel R; Endris V; Noske A; Weichert W; Schirmacher P; Denkert C; Stenzinger A
Genes Chromosomes Cancer; 2017 Oct; 56(10):758-766. PubMed ID: 28639280
[TBL] [Abstract][Full Text] [Related]
40. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
